The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Skin Cancer Screening and Surveillance

Systematic approach to early detection of skin cancers (melanoma, basal cell carcinoma BCC, squamous cell carcinoma SCC) through total body skin examination (TBSE), patient self-examination, dermoscopy-based evaluation, digital photographic surveillance, and risk-stratified follow-up programs; includes annual to bi-annual screening for high-risk patients (multiple atypical nevi, family history of melanoma, prior skin cancer, immunosuppression, fair skin with significant UV exposure), use of ABCDE warning signs (Asymmetry, Border irregularity, Color variation, Diameter > 6mm, Evolution) and Ugly Duckling sign for self-screening, total body photography (TBP) with serial monitoring, sequential digital dermoscopy imaging (SDDI) for individual lesion tracking, and reflectance confocal microscopy (RCM) for ambiguous lesions; primary screening reduces melanoma mortality through detection of thinner, more curable lesions while balancing harms of overdiagnosis and unnecessary biopsies.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Skin Cancer Screening and Surveillance?

Skin cancer screening and surveillance encompasses the systematic clinical and technological approach to early detection of skin cancers (melanoma, basal cell carcinoma, squamous cell carcinoma, less common — Merkel cell carcinoma, dermatofibrosarcoma, cutaneous lymphoma, others) and ongoing monitoring of high-risk individuals to prevent advanced disease and reduce mortality. Skin cancer represents the most common cancer worldwide with significant impact on morbidity and mortality, particularly melanoma which accounts for 1-2 percent of skin cancers but 80 percent of skin cancer deaths.

Epidemiology and importance: 1) Melanoma — fifth most common cancer in US, incidence increased 50 percent over past 20 years, lifetime risk approximately 1 in 50 in US population; mortality reduced 50 percent when detected at thin stage (< 1 mm Breslow thickness — 5-year survival > 95 percent) versus thick stage (5-year survival < 50 percent for > 4 mm); 2) Basal cell carcinoma — most common skin cancer (3.6 million US cases annually); locally invasive but rarely metastasizes (< 0.1 percent); higher incidence in elderly, fair-skinned populations with chronic sun exposure; 3) Squamous cell carcinoma — second most common skin cancer; can metastasize (1-5 percent of typical SCCs, 10-30 percent of high-risk SCCs — large size > 2 cm, deep invasion, perineural invasion, immunosuppressed patients, ear and lip locations); 4) Other skin cancers include Merkel cell carcinoma (rare, aggressive — Merkel cell polyomavirus association), dermatofibrosarcoma protuberans, cutaneous T-cell lymphoma, Kaposi sarcoma, sebaceous carcinoma, etc.

Risk factors and risk stratification: 1) Highest risk patients (annual or more frequent surveillance recommended) — personal history of melanoma, multiple atypical nevi (> 50 nevi, multiple atypical-appearing nevi), familial atypical multiple mole melanoma syndrome (FAMMM, CDKN2A mutations), BAP1 tumor predisposition syndrome (BAP1 mutations), xeroderma pigmentosum, immunosuppression (organ transplant recipients have 60-100x risk SCC, 6-10x risk BCC, 2-3x melanoma; HIV, lymphoma, immunosuppressive medications), albinism; 2) High risk — first-degree relative with melanoma, personal history of nonmelanoma skin cancer, fair skin (Fitzpatrick I-II), red or blonde hair, blue eyes, history of severe sunburns particularly childhood, intense UV exposure (occupational, recreational), tanning bed use; 3) Moderate risk — Fitzpatrick III skin, moderate UV exposure history, age > 50, male sex; 4) Lower risk — Fitzpatrick IV-VI skin, minimal UV exposure, younger age (although still at risk for some cancers including melanoma in unusual locations like palms, soles, mucosa, nails in darker-skinned individuals).

Screening modalities and components: 1) Total body skin examination (TBSE) — comprehensive systematic examination from scalp to soles, including frequently missed sites (scalp under hair, ears, between buttocks, palms and soles, between toes, genital and perianal areas, mucosal surfaces, nails); good lighting, magnification (head loupe with 2-4x or dermoscopy), patient gowned and able to be repositioned for full skin visualization; 2) Self-skin examination — patient education on monthly self-skin examination using ABCDE warning signs (A — Asymmetry of mole; B — Border irregularity; C — Color variation; D — Diameter > 6 mm; E — Evolution or changes), Ugly Duckling sign (lesion that looks different from rest of patient's nevi), use of mirrors for hard-to-see areas, partner assistance for back; education materials and apps available; effective when combined with professional examination; 3) Dermoscopy — significantly improves diagnostic accuracy (sensitivity 80-90 percent versus 60 percent naked eye, specificity 60-90 percent); essential for evaluation of pigmented lesions and recognition of suspicious features; algorithms (pattern analysis, ABCD, 7-point checklist, 3-point checklist, chaos and clues — see Dermoscopy Basic Algorithms); 4) Total body photography (TBP) — comprehensive set of standardized full-body photographs (typical 25-50 image positions covering entire body surface) at baseline and serial follow-up for comparison; primary advantage of detecting new lesions and changes in existing lesions; commercial systems (Vectra WB360 with 360-degree imaging, ATBM Bodystudio with FotoFinder, MoleMax HD); 5) Sequential digital dermoscopy imaging (SDDI) — close-up dermoscopic photographs of individual atypical-appearing nevi at 3-12 month intervals; identification of significant changes warrants biopsy; 6) Reflectance confocal microscopy (RCM) — quasi-histologic in vivo cellular imaging using near-infrared laser; particularly useful for ambiguous facial lentigines, equivocal melanocytic lesions; available in specialty centers; 7) AI-assisted screening — emerging technology with mobile applications and clinical decision support tools (DermEngine, SkinVision, FotoFinder Moleanalyzer, Melaknow), some FDA-cleared for diagnostic decision support.

Symptoms

New mole appearing in adulthood
Change in existing mole (size, shape, color, surface)
ABCDE warning signs in mole (Asymmetry, Border, Color, Diameter > 6mm, Evolution)
Ugly duckling sign — mole looks different from rest of patient's moles
Bleeding mole
Itching or pain in mole
Crusting or non-healing skin lesion
Pearly papule on sun-exposed skin (suspicious for BCC)
Scaly nodule or non-healing ulcer (suspicious for SCC)
Pink shiny patch (basal cell carcinoma morphology)
Ulcer that doesn't heal in 4 weeks
Patient self-noticed suspicious lesion
Multiple atypical-appearing moles
Family member with melanoma noted
Personal history of skin cancer requiring surveillance
Immunosuppression beginning surveillance recommended
Pre-transplant skin cancer screening
Pediatric or adolescent atypical mole concerns
Photoaged skin requiring evaluation

Risk Factors

Personal history of melanoma (any stage, any time)
Personal history of nonmelanoma skin cancer (BCC, SCC)
Family history of melanoma in first-degree relative
Multiple atypical nevi (dysplastic nevus syndrome)
More than 50 acquired nevi
CDKN2A mutation (familial melanoma)
BAP1 tumor predisposition syndrome
Xeroderma pigmentosum
Werner syndrome
Albinism
Fair skin (Fitzpatrick types I-II)
Red or blonde hair, blue eyes
History of severe sunburns (especially childhood blistering sunburns)
Excessive cumulative UV exposure
Tanning bed use (any history)
Outdoor occupation
Outdoor recreational activities (surfing, golf, tennis)
Sunny climate residence
Immunosuppression (organ transplant recipient, HIV, hematologic malignancy, immunosuppressive medications including TNF inhibitors)
Photo-aged skin
Multiple actinic keratoses (precancerous)
Prior radiation therapy in skin field
Chronic non-healing wound (Marjolin ulcer)
Smoking (slight increased risk)
Older age (cumulative UV exposure)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New mole appearing in adulthood — even if asymptomatic
  • Existing mole changing in any way (size, shape, color)
  • Symptomatic mole (itchy, painful, bleeding)
  • Ugly duckling mole — looks different from your other moles
  • Non-healing skin sore or ulcer (4+ weeks)
  • Pearly translucent papule on sun-exposed skin
  • Scaly red persistent patch (Bowen's disease, BCC)
  • Family history of melanoma — establish baseline
  • Personal history of skin cancer — surveillance schedule
  • Multiple moles (>50) for total body skin examination
  • Atypical-appearing moles for evaluation
  • Patient anxious about skin lesions
  • High-risk patient for surveillance program
  • Annual skin cancer screening recommended
  • Immunosuppression initiation — baseline evaluation
  • Pre-transplant skin cancer assessment
  • Pediatric atypical mole or congenital nevus
  • Photoaged skin with multiple lesions
  • Tanning bed use history
  • Severe sunburn history
  • Outdoor occupation or significant UV exposure

Treatment Methods

01
Initial assessment and risk stratification: 1) Comprehensive history including personal cancer history, family history of melanoma and other skin cancers, sun exposure history (occupational and recreational, sunburns particularly blistering), tanning bed use, skin type assessment, current and prior immunosuppression, medications, current symptoms; 2) Physical examination — complete head-to-toe skin examination including scalp, ears, mucosae, palms, soles, nails, intergluteal, perianal, genital areas; documentation of all lesions with photography or sketch maps; 3) Risk stratification using validated tools (Williams nomogram, MelaNostrum risk score) and clinical judgment; 4) Determination of surveillance frequency based on risk (high-risk every 3-6 months, moderate-risk every 6-12 months, lower-risk annual or as indicated)
02
Total body skin examination protocol: 1) Patient gowned and prepared in well-lit examination room; 2) Systematic examination starting with scalp and progressing distally; 3) Head — scalp parted methodically, ears (anterior, posterior, ear canal opening), face including eyelids and behind ears, lips and inside mouth, nose; 4) Neck and trunk — anterior and posterior, axillae, breasts in women (lifting for examination of inferior breast surface), abdomen including umbilicus and pubic area, back including buttocks, intergluteal cleft; 5) Upper extremities — shoulders, anterior and posterior arms, axillae, antecubital, forearms, wrists, hands (palms and dorsum), interdigital spaces, fingernails (Hutchinson sign on nail folds); 6) Lower extremities — anterior and posterior thighs, knees (anterior and popliteal), legs anteriorly and posteriorly, ankles, feet (dorsum and soles), interdigital spaces, toenails; 7) Inspection of any unusual or symptomatic lesions with dermoscopy; 8) Photographic documentation of suspicious lesions for tracking; 9) Patient instruction on self-examination and signs of concern
03
Dermoscopy in screening: 1) Use polarized or non-polarized handheld dermoscope (Heine, DermLite, Nikon series, integrated systems with FotoFinder); 2) Application of immersion fluid (alcohol gel, ultrasound gel) for non-polarized; 3) Systematic evaluation of suspicious lesions using selected algorithm (pattern analysis, ABCD, 7-point checklist, 3-point checklist, chaos and clues); 4) Special locations require modified algorithms (acral, facial, mucosal, nail); 5) Documentation with photography for serial monitoring or referral; 6) Decision making — reassurance for clearly benign lesions, monitoring for low-suspicion atypical lesions (3-6 months), biopsy or excision for higher-suspicion lesions
04
Digital photographic surveillance and TBP: 1) Indications include patients with multiple atypical nevi, high-risk individuals, dysplastic nevus syndrome; 2) Standardized photographic protocol — patient in standardized positions (typical 25-50 image positions including frontal, lateral, posterior, multiple oblique views, scalp, hands, feet); 3) High-resolution professional photography or specialized commercial systems (Vectra WB360 with 360-degree imaging from 92 cameras simultaneously, FotoFinder ATBM Bodystudio, MoleMax HD, Canfield Imaging); 4) Baseline imaging at initial high-risk patient evaluation; 5) Follow-up imaging at 3-12 month intervals based on risk; 6) Software-assisted comparison detecting new lesions and changes in existing lesions; 7) Sequential digital dermoscopy imaging (SDDI) for individual atypical lesions — close-up dermoscopic photographs at 3-12 month intervals; 8) Decision making based on visible changes (new lesions warrant biopsy in high-risk patients, changes > 30 percent in size or new asymmetric features in atypical nevi warrant biopsy)
05
Patient education and self-skin examination: 1) Detailed instruction on monthly self-skin examination using mirrors and partner assistance; 2) ABCDE warning signs education with visual aids; 3) Ugly duckling sign concept; 4) Skin self-examination apps and educational materials; 5) Photoprotection counseling — sunscreen broad-spectrum SPF 30+, reapplied every 2 hours and after swimming; protective clothing UPF-rated; broad-brimmed hat; UV-protective sunglasses; sun avoidance during peak hours 10 AM - 4 PM; 6) Tanning bed avoidance — Class I carcinogen by IARC; especially harmful for those starting < age 35 (75 percent increased melanoma risk); 7) Healthy diet and lifestyle counseling; 8) Vitamin D considerations (oral supplementation reasonable to avoid sun-exposure-related vitamin D arguments); 9) Smoking cessation
06
Reflectance confocal microscopy (RCM) for ambiguous lesions: 1) Indications include ambiguous facial lesions (lentigo maligna versus benign solar lentigo), equivocal melanocytic lesions, evaluation of basal cell carcinoma margins, monitoring of complex lesions; 2) Available at specialty centers (limited availability); 3) Quasi-histologic imaging at cellular resolution using near-infrared laser at 830 nm; 4) Provides information about cellular and tissue patterns similar to histopathology; 5) Particularly useful in difficult-to-biopsy locations (face, eyelid, lip); 6) Reduces unnecessary biopsies of benign lesions when integrated with dermoscopy
07
Biopsy and management decisions: 1) Suspicious lesions require histopathologic confirmation; 2) Biopsy techniques — excisional biopsy (preferred for melanocytic lesions when possible), incisional biopsy or punch biopsy for large lesions, shave biopsy for non-melanocytic suspicious lesions, scrape biopsy for SCC in situ or AK; 3) Margins for excisional biopsy melanocytic lesions — 1-3 mm margin clinically; 4) Following diagnosis — staged based on histopathology; melanoma — Breslow thickness, ulceration, mitotic rate determine prognosis and treatment; BCC and SCC — surgical excision with appropriate margins; 5) Sentinel lymph node biopsy considerations for melanoma > 0.8 mm Breslow thickness with risk factors; 6) Subspecialty referral for complex cases (Mohs surgery for facial BCC/SCC, melanoma surgical oncology for advanced disease)
08
Long-term surveillance protocols: 1) High-risk patients (history of melanoma, multiple atypical nevi, FAMMM, BAP1) — surveillance every 3-6 months indefinitely with dermoscopy and TBP; 2) Moderate-risk patients (history of nonmelanoma skin cancer, fair skin with significant UV exposure, family history) — every 6-12 months; 3) Lower-risk patients — annual or as indicated; 4) Lifetime surveillance recommended for patients with melanoma history (recurrence risk extends decades); 5) Continued education on photoprotection and self-examination; 6) Documentation of all examinations and follow-up plans; 7) Communication with primary care providers and other specialists; 8) Modification based on changes in risk profile (immunosuppression initiation, family history changes)
09
Special populations and considerations: 1) Pediatric — most lesions benign, but increasing melanoma incidence in adolescents; congenital nevi require risk-adjusted surveillance; familial syndromes; 2) Pregnancy — pregnancy-associated melanoma; many nevi may change appearance during pregnancy; 3) Immunosuppressed patients — organ transplant recipients have dramatically increased SCC risk (60-100x), require frequent intensive surveillance; 4) Skin of color — melanoma less common but more often diagnosed at advanced stage; acral, mucosal, nail melanomas more common; 5) Elderly — high incidence of nonmelanoma skin cancers, often multiple lesions; 6) Outdoor workers and athletes — counseling on photoprotection; 7) Patients with chronic non-healing wounds (Marjolin ulcer); 8) Cultural and religious considerations affecting examination practices
10
Quality assurance and outcomes: 1) Standardized examination protocols and documentation; 2) Photographic standardization for serial comparison; 3) Continuous medical education for screening clinicians; 4) Quality improvement metrics (lesions per appointment, biopsy yield, melanoma detection at thin stage, patient satisfaction); 5) Integration with electronic medical records for tracking; 6) Patient registries for high-risk individuals; 7) Outcomes — early detection programs reduce melanoma-related mortality, particularly in high-risk populations; 8) Cost-effectiveness analysis supports screening of high-risk populations; population-based screening of average risk remains controversial (USPSTF I statement — insufficient evidence for or against, but most dermatology societies recommend periodic skin examination)

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.